THIS WEBSITE USES COOKIES

We use technically necessary cookies to make this website work. With your consent, we also use Google Analytics to evaluate the use of our website statistically (“Statistics”) and embed videos from YouTube and maps from Google Maps (“External media”). In doing so, data is transferred to Google, including to the USA. You can change or withdraw your selection at any time via the cookie settings at the bottom of the page. Further information can be found in our privacy policy and cookie statement.

Dermatology

Photo credits: pixabay.com

Commented by Nico Popp on November 4th, 2026 | 05:42 CET

Dermatology with Tailwinds: How Galderma Is Deploying Billions, Vidac Pharma Awaits Crucial Clinical Data and Biofrontera Expands

Biotech
Dermatology
Cellular metabolism
Forms of therapy

Dermatological research is undergoing a phase of rapid growth. While established corporations generate enormous revenues in systemic therapies, new, targeted approaches to treating precancerous skin lesions are on the verge of clinical validation. High growth rates at Galderma, new approval decisions by the US Food and Drug Administration (FDA) for Biofrontera, and upcoming trial data at Vidac Pharma show how significantly skin disease treatment is changing. We show what opportunities this could create for investors.

Read